Marcia S. Brose, MD, PhD, from the University of Pennsylvania, discusses the treatment of anaplastic thyroid cancer (ATC) and the FACT2 study.
Marcia S. Brose, MD, PhD, assistant professor, Abramson Cancer Center, Department of Otolaryngology, Head & Neck Surgery, Department of Medicine, Division of Hematology/Oncology, Department of Dermatology, University of Pennsylvania, discusses the treatment of anaplastic thyroid cancer (ATC) and the FACT2 study.
ATC is a devastating disease, Brose says, and there remains a need for agents that are effective. It may be possible to combine targeted agents, as some have demonstrated limited activity.
Outside the U.S., there is a push to move forward with the FACT2 study, which aims to analyze the efficacy of fosbretabulin given with chemotherapy (paclitaxel and carboplatin). Brose hopes that the results will have an impact on the treatment of ATC in the U.S.